TissGeneSummary for CXCL17 |
Gene summary |
Basic gene information | Gene symbol | CXCL17 |
Gene name | chemokine (C-X-C motif) ligand 17 | |
Synonyms | DMC|Dcip1|UNQ473|VCC-1|VCC1 | |
Cytomap | UCSC genome browser: 19q13.2 | |
Type of gene | protein-coding | |
RefGenes | NM_198477.1, | |
Description | C-X-C motif chemokine 17VEGF co-regulated chemokine 1VEGF coregulated chemokine 1dendritic cell and monocyte chemokine-like protein | |
Modification date | 20141207 | |
dbXrefs | MIM : 611387 | |
HGNC : HGNC | ||
HPRD : 18264 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_CXCL17 | |
BioGPS: 284340 | ||
Pathway | NCI Pathway Interaction Database: CXCL17 | |
KEGG: CXCL17 | ||
REACTOME: CXCL17 | ||
Pathway Commons: CXCL17 | ||
Context | iHOP: CXCL17 | |
ligand binding site mutation search in PubMed: CXCL17 | ||
UCL Cancer Institute: CXCL17 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Stomach | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | STAD | |
Reference showing the relevant tissue of CXCL17 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for CXCL17 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
THCA | 1.776094632 | -1.430618927 | 3.206713559 | 7.29E-12 | 5.68E-11 |
HNSC | 2.611402594 | 5.830865385 | -3.219462791 | 3.64E-09 | 5.02E-08 |
LUSC | 3.956613675 | 7.118094067 | -3.161480392 | 6.04E-14 | 3.21E-13 |
STAD | 2.869320109 | 5.330423234 | -2.461103125 | 0.0144 | 0.046133333 |
COAD | -3.092820036 | -4.339362343 | 1.246542308 | 0.00473 | 0.011388385 |
PRAD | 0.786872272 | 2.206756887 | -1.419884615 | 0.00356 | 0.009693755 |
LUAD | 6.237257285 | 7.305271078 | -1.068013793 | 0.000924 | 0.002033888 |
Top |
TissGene-miRNA for CXCL17 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for CXCL17 |
TissGeneSNV for CXCL17 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.M1I | BRCA | 1 |
p.E51G | LIHC | 1 |
p.L8R | COAD | 1 |
p.H93N | STAD | 1 |
p.F80L | BLCA | 1 |
Top |
TissGeneCNV for CXCL17 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for CXCL17 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
TCGAfusionPortal | PRADA | GBM | TCGA-32-1970-01A | AC003682.1-CXCL17 | In-frame | Chr19:58063995 | Chr19:42938008 |
Top |
TissGeneNet for CXCL17 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for CXCL17 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for CXCL17 |
TissGeneDrug for CXCL17 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for CXCL17 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C2239176 | Liver carcinoma | 3 | BeFree |
umls:C0596263 | Carcinogenesis | 2 | BeFree |
umls:C0007847 | Malignant tumor of cervix | 1 | BeFree |
umls:C0009402 | Colorectal Carcinoma | 1 | BeFree |
umls:C0027627 | Neoplasm Metastasis | 1 | BeFree |
umls:C0085110 | Severe Combined Immunodeficiency | 1 | BeFree |
umls:C0178874 | Tumor Progression | 1 | BeFree |
umls:C0242379 | Malignant neoplasm of lung | 1 | BeFree |
umls:C0265286 | Dyggve-Melchior-Clausen syndrome | 1 | BeFree |
umls:C0278484 | Malignant neoplasm of colon stage IV | 1 | BeFree |
umls:C0302592 | Cervix carcinoma | 1 | BeFree |
umls:C0684249 | Carcinoma of lung | 1 | BeFree |
umls:C1519670 | Tumor Angiogenesis | 1 | BeFree |